Northstrive Biosciences completes Phase II of AI Development Program with Yuva Biosciences.

Northstrive Biosciences and Yuva Biosciences completed Phase II of their AI Development Program, which aims to discover and develop novel treatments for obesity, type 2 diabetes, and cardiometabolic conditions. YuvaBio compiled a list of small molecule candidates that promote mitochondrial health to combat these diseases.

Northstrive Biosciences Inc. and Yuva Biosciences Inc. have announced the successful completion of Phase II of their AI Development Program, a collaboration aimed at discovering and developing novel pharmaceutical treatments for obesity, type 2 diabetes, and other cardiometabolic conditions [1].

The program leverages MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to identify and develop small molecule candidates that promote mitochondrial health. During Phase II, YuvaBio compiled a targeted collection of compounds from 12 curated libraries, designed to include molecules with activity across key disease areas—obesity, cardiometabolic disorders, and lipid & glucose metabolism. MitoNova™ screened the aggregated chemical space to evaluate the predicted impact on a specified target involved in muscle preservation and metabolic health [1].

YuvaBio presented Northstrive with a shortlist of compounds ready for biological validation in vitro. Northstrive now has the opportunity to review these compounds and analyze their potential for experimental testing and clinical development [1].

Northstrive Biosciences Inc. is a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), focusing on the development and acquisition of cutting-edge aesthetic medicines. Their lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists [1].

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. The company is committed to exploring opportunities in multiple sectors to maximize growth and value [1].

Forward-looking statements in the press release highlight potential risks and uncertainties, including the possibility that actual results may differ materially from anticipated results. Investors are urged to review the "Risk Factors" section of PMGC Holdings’ filings with the SEC for more information [1].

References:
[1] https://www.globenewswire.com/news-release/2025/09/04/3144667/0/en/Northstrive-Biosciences-Announces-Completion-of-Phase-II-of-AI-Development-Program-with-YuvaBio-Using-MitoNova-Artificial-Intelligence-AI-Platform-to-Develop-Therapies-for-Obesity-.html